<DOC>
	<DOCNO>NCT00531310</DOCNO>
	<brief_summary>CML , malignant disorder stem cell , characterize increase immature mature myeloid , erythroid , lymphoid cell , well platelets peripheral blood . The cytogenetic hallmark CML Philadelphia ( Ph ) chromosome find malignant cell 95 % patient . CML comprise 7-20 % leukemia overall incidence general population estimate 1 2 per 100,000 . The peak incidence occur fifth decade , however , age group , include child , affect . The reported environmental risk factor exposure excessive ionizing radiation document small percentage patient . Clinically , CML characterize initial chronic phase patient may report mild constitutional symptom ; however , 40-50 % asymptomatic diagnose base upon abnormal blood count discover routine examination . The chronic phase typically last three five year , follow accelerated phase distinguish progressive systemic symptom , increase resistance conventional chemotherapy , rise peripheral blood bone marrow blast count . This evolve rapidly blastic crisis characterize immature cell resemble blast characteristic acute leukemia . The presence 30 % blastic cell blood marrow diagnostic final blastic phase typically fatal within 3 6 month . The primary treatment option CML traditionally monotherapy either busulfan hydroxyurea . Both agent able control clinical symptom associate CML , well induce hematological remission 80 % chronic phase patient . However , complete cytogenetic remission either agent rare , neither able prevent eventual progression terminal blastic phase ; therefore , therapy consider palliative . The primary purpose clinical research trial study feasibility reduce intensity allogenic transplant CML . This study also determine side effect well response rate .</brief_summary>
	<brief_title>Reduced Intensity AlloSCT ( CML ) With Persistent Disease</brief_title>
	<detailed_description>Further study detail provide Columbia University , Division Pediatric Blood Marrow Transplantation . STUDY DESIGN : Patients le 30 year age CML 1st 2nd chronic phase 1st accelerated phase match related donor , unrelated cord blood donor , unrelated adult donor , receive 6 day IV Fludarabine , 4 dos IV Busulfex , 5 dos Alemtuzumab . Patients persistant RT-PCR positive BCR-Abl and/or Philadelphia chromosome positivity cytogentics Day + 100 matched related donor would receive DLIx1 . If still BCR-Abl Philadelphia chromosome positive Day +180 match related donor , patient would receive second dose DLI . All patient receive STI-571 ( Gleevec ) hematological reconstitution . Studies immune reconstitution , chimersim , MRD perform postt AlloSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age : Patient must less 30 year age . Consent : Patient patient 's legally authorized guardian must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) , must sign informed consent accordance institutional policy approve U.S. Department Health Human Services . Organ Function : Patient must adequate organ function Adequate renal function define : Serum creatinine 1.5 x normal , Creatinine clearance radioisotope GFR &gt; 40 ml/min/m2 &gt; 60 ml/min/1.73 m2 equivalent GFR determine institutional normal range Adequate liver function define : Total bilirubin &lt; 2.5 x normal ; SGOT ( AST ) SGPT ( ALT ) &lt; 5.0 x normal Adequate cardiac function define : Shortening fraction &gt; 25 % echocardiogram , Ejection fraction &gt; 40 % radionuclide angiogram echocardiogram Adequate pulmonary function define : DLCO &gt; 40 % pulmonary function test For child uncooperative , evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % room air . Disease Status Patients CML either follow : Patients 1st 2nd chronic phase Patients 1st 2nd accelerated phase Patient blast crisis Patient 3rd great chronic phase Patient 3rd great accelerate phase woman pregnant ineligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>CML</keyword>
	<keyword>allogeneic SCT</keyword>
	<keyword>match family donor</keyword>
	<keyword>unrelated donor</keyword>
	<keyword>cord blood donor</keyword>
	<keyword>persistent disease</keyword>
</DOC>